Navigation Links
PROLENE Hernia System

ProductsPROLENE Hernia System
Company Ethicon, Inc.
Item PROLENE Hernia System
Features 
  • A tension-free repair that protects both the femoral and inguinal regions (myopectineal orifice) from recurrence
  • The underlay patch lies flat in preperitoneal space, providing a double-layered reconstruction of the transversalis fascia
  • A versatile product that is indicated for all abdominal wall hernia repairs
  • All the advantages of a secure posterior repair, from a simple anterior approach
  • A device that provides the maximum allowable flat surface for effective tissue ingrowth in inguinal hernia repair
  • A repair that is less bulky than preformed plugs thereby minimizing patient discomfort.
  • The underlay mesh that when deployed protects the entire Myopectineal orifice.
  • Simple, reliable, fast, and cost effective repair.
  • Combines the three most common tension free repair techniques used today.
  • Virtually eliminates the chance of recurrence.
  • Potential for rapid return to normal activities.
  • Easy to use.
  • Requires minimal or no sutures to secure in place.
  • Less bulk than preformed plugs.
  • Large pore sizes to support fast tissue in-growth and good capillary penetration.
  • Less expensive than other mesh devices used in hernia repair.
  • Minimal shrinkage as a result of scar tissue maturation; unlike the plug device which has been shown to lose up to 70% of its volume as a result of scar tissue maturation.
  • Description The PROLENE polypropylene Hernia System is a sterile, pre-shaped, three-dimensional device constructed of an onlay patch connected by a mesh cylinder to a circular underlay patch. The PROLENE Hernia System's 3 in 1 unique and innovative design combines the three most popular tension free techniques utilized today in the repair of inguinal hernias. Its Onlay Patch covers the entire floor of the canal; it overlaps the pubic tubercle for added support, and provides the security of conventional patch techniques. Its Connector provides the simplicity of a plug repair. Additionally, it secures the underlay patch to prevent migration. Its profile is a significant improvement over the bulk of conventional plugs. The Underlay Patch, like a laparoscopic repair, provides posterior support; however it accomplishes that support from a much simple anterior approach. This underlay patch lays in the preperitoneal space and opens to cover the entire myopectineal orifice. This key and exclusive feature of the PROLENE Hernia System ensures that both the femoral and inguinal regions are protected to minimize the possibility of recurrence.
    Info Ethicon, Inc.
    Customer Service: (800) 4-ETHICON
    Web site: http://www.ethicon.com/

    Related medicine products :

    1. PROLENE polypropylene mesh
    2. Surgisis® GOLD™ Hernia Repair Grafts
    3. Surgisis® IHM™ Inguinal Hernia Matrix
    4. Bard Kugel® Hernia Patch
    5. Bard Composix Kugel Hernia Patch
    6. Self-Forming Hernia Mesh Plugs
    7. Surgisis EXL Hernia Repair Graft
    8. Silicone Oil Cannula System - 20 Gauge
    9. Silicone Oil Cannula System - 19 Gauge
    10. SuperVu Galilean System
    11. KOWA nonmyd 7 / VK-2 Digital Imaging System
    Inquire...
    ... The Trinity Biotech Captia™ Mumps IgG ... the detection and quantitative determination of IgG ... Individual serum specimens may be used for ... acute and convalescent, may be used to ...
    ... AUTOMATION, INC. (DAI) Mumps IgG ... intended for the detection and ... to Mumps virus in human ... be used for the determination ...
    ... Corporation announced the launch of the ... first bi-directional cooled-tip catheter available in the ... offers physicians the benefits of cooled ablation ... the Boston Scientific Blazer(R) catheter platform. ,Cooled ...
    Medicine Products:
    (Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Social networking ... new study. For people who are obese, sites ... convenient source of support from doctors as well as ... media over other methods is that it offers the ... for day-to-day use when compared to traditional approaches," the ...
    (Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
    (Date:9/17/2014)... Sept. 17, 2014 (HealthDay News) -- Positive messages about ... people kick the habit, a new study suggests. ... better to "loss-framed" messages about the harmful effects of ... whenever they want benefit more from "gain-framed," or positive, ... The researchers concluded that using a mix of both ...
    (Date:9/17/2014)... 2014 Many countries choose to kill ... immunizations. The total number of poultry exceeds 10 billion ... will result in huge losses. Therefore, it is quite ... , Avian influenza vaccines have been used for more ... China began to use H5N1 avian influenza vaccines voluntarily ...
    (Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
    Breaking Medicine News(10 mins):Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6
    ... Campath, CAMBRIDGE, Mass. and WAYNE, N.J., Sept. ... Bayer HealthCare Pharmaceuticals Inc.,(NYSE: BAY ) today ... has approved a supplemental biologics license application (sBLA) ... for the treatment of B-cell chronic lymphocytic leukemia ...
    ... LLC, today announced the,U.S. Food and Drug Administration ... use in intervertebral fusion procedures.,Included are versions to ... without the need for supplemental fixation. Fusion ... performed by,neurosurgeons and orthopedic spine surgeons. The InterPlate ...
    ... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... chronic,lymphocytic leukemia (CLL). CLL is a slowly progressing ... new cases diagnosed every year in,the United States, ...
    ... new implant for marketing, NEW YORK, Sept. 21 ... products, technology and education for the,small bone and joint ... Spacer has been cleared by the FDA for marketing ... of surgically implanted, degradable,spacers to four applications with two ...
    ... you eat the right grains for breakfast, such as ... sugar is facilitated after breakfast, lunch, and dinner. It ... this effect all day. This is due to a ... of indigestible carbohydrates that occur in certain grain products. ...
    ... Aviv Universitys Sackler School of Medicine is, quite simply, a ... of a small number of surgeons in the world who ... has developed a novel laser device that promises to revolutionize ... now, is expected to give most practicing eye surgeons the ...
    Cached Medicine News:Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 3Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 4Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 5Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 6Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 2Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 3Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 4Health News:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 5Health News:Right breakfast bread keeps blood sugar in check all day 2Health News:Glaucoma surgery in the blink of an eye 2
    (Date:9/17/2014)... 17, 2014 /PRNewswire-iReach/ -- ChemImage announced today ... improvements in the development of imaging technology ... normal and diseased tissue that minimizes the ... procedures, lowers surgical costs and potentially enhances ... The clinical and scientific teams ...
    (Date:9/17/2014)... 17, 2014 Prostate Oncology Specialists announces ... to educate men about new imaging technology destined ... prostate. Annually, a million men undergo random needle ... MRI (MP-MRI) of the prostate gland is non-invasive ... need to be fully informed of their alternatives. ...
    (Date:9/17/2014)... , Sept. 17, 2014  Rebiotix Inc. announced this morning ... lead product candidate, RBX2660 (microbiota suspension) will be presented in ... conference in Philadelphia from October 8-12. ... during the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 ...
    Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4